Effects of surgical menopause and estrogen replacement therapy on serum paraoxonase activity and plasma malondialdehyde concentration

Gynecologic and Obstetric Investigation

Volumn 59, Issue 2, 2005, Pages 108-112

  Kumru, Selahattin ^a,b   Aydin, Suleyman ^a   Aras, Azer ^a   Gursu, M F ^a   Gulcu, Funda ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Estrogen replacement therapy; Lipid peroxidation; Menopause; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PON1 PROTEIN, HUMAN;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; HUMAN; LIPID PEROXIDATION; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; STATISTICAL SIGNIFICANCE; UTERUS MYOMA; BLOOD; DRUG EFFECT; HYSTERECTOMY; LEIOMYOMA; OVARIECTOMY; TREATMENT OUTCOME; UTERUS CANCER;

ARYLDIALKYLPHOSPHATASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOMA; LIPID PEROXIDATION; MALONDIALDEHYDE; MENOPAUSE; OVARIECTOMY; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 18944369383     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082647     Document Type: Article

References (37)

1. The Practice Committee of the American Society for Reproductive Medicine: Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2004;1:231-241.
2. Rapp SR, Espeland MA, Shumaker SA, et al: Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2663-2672.
3. Stoks SJ: The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol 1995;6:205-228.
4. Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bidzinska B, Milewicz A, Antonowicz-Juchniewicz J, Andrzejak R: Serum lipid peroxide levels and erythrocyte glutathione peroxidase and superoxide dismutase activity in premenopausal and postmenopausal women. Gynecol Endocrinol 2001;4:298-303.
5. Ozden S, Dildar K, Kadir YH, Gulizar K: The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas 2001;38:165-170.
6. Falkeborn M, Lithell H, Persson I, Vessby B, Naessen T: Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial. Climacteric 2002;3:240-248.
7. Blatter MC, James RW, Messmer S, Barja F, Pometta D: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993;211:871-879.
8. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;3:598-608.
9. Watson AD, Berliner JA, Hama SY, et al: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-2891.
10. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
11. Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM: Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic post-menopausal women. Metabolism 2001;3:319-324.
12. Bwege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978;52:303-310.
13. Dubravka J, Milena T, Branka R, Vrea SR, Elsa R, Martin B: Serum paraoxonase activities in the hemodialyzed uremic patients: Cohort study. Clin Sci 2001;42:146-150.
14. Linton MF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 2003;27(suppl 3):35-40.
15. Luoma PV: Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol 1997;81:57-64.
16. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN: Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-199.
17. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN: Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-349.
18. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A: Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004;1:59-66.
19. Boemi M, Sirolla C, Testa R, Cenerelli S, Fumelli P, James RW: Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in type 2 diabetic patients. Diabet Med 2004;5:423-427.
20. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I: Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002;2:63-67.
21. Mehmetcik G, Toker G, Uysal M: Endogenous and copper-induced lipid peroxidation and antioxidant activity of serum in hypercholesterolemic subjects. Horm Metab Res 1997;29:63.
22. Mutlu-Turkoglu U, Dogru-Abbasoglu S, Aykac-Toker G, Mirsal H, Beyazyurek M, Uysal M: Increased lipid and protein oxidation and DNA damage in patients with chronic alcoholism. J Lab Clin Med 2000;136:287.
23. Mutlu-Turkoglu U, Ilhan E, Oztezcan S, Kuru A, Aykac-Toker G, Uysal M: Age-related increases in plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in elderly subjects. Clin Biochem 2003;5:397-400.
24. Abou-Seif MA, Youssef AA: Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004;2:161-170.
25. Tamer L, Sucu N, Polat G, Ercan B, Aytacoglu B, Yucebilgic G, Unlu A, Dikmengil M, Atik U: Decreased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serum malondialdehyde in atherosclerotic patients. Arch Med Res 2002;3:257-260.
26. Ates NA, Yildirim O, Tamer L, Unlu A, Ercan B, Muslu N, Kanik A, Hatungil R, Atik U: Plasma catalase activity and malondialdehyde level in patients with cataract. Eye 2004;8:785-788.
27. Dib M, Garrel C, Favier A, Robin V, Desnuelle C: Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease? J Neurol 2002;4:367-374.
28. Naziroglu M, Simsek M, Simsek H, Aydilek N, Ozcan Z, Atilgan R: The effects of hormone replacement therapy combined with vitamins C and E on antioxidants levels and lipid profiles in postmenopausal women with type 2 diabetes. Clin Chim Acta 2004;1-2:63-71.
29. Ruiz-Larrea MB, Martin C, Martinez R, Navarro R, Lacort M, Miller NJ: Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000;2:179-188.
30. Stevenson JC, Crook D, Godsland IF: Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.
31. Erenus M, Karakoc B, Gurler A: Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001;4:228-234.
32. Writing Group for the Women's Health Initiative Investigators: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
33. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al, HERS Research Group: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
34. Powledge TM: NIH terminates WHI oestrogen-only study. Lancet 2004;9412:870.
35. Sumino H, Ichikawa S, Sakamoto H, Sawada Y, Kumakura H, Takayama Y, Sakamaki T, Kurabayashi M: Effects of conjugated equine estrogenand medroxyprogesterone acetate on lipoprotein(a) and other lipoproteins in Japanese postmenopausal women with and without dyslipidemia. Horm Res 2004;1:1-9.
36. Sitruk-Ware RL: Hormone therapy and the cardiovascular system: The critical role of progestins. Climacteric 2003;6(suppl 3):21-28.
37. Williams JK, Suparto I: Hormone replacement therapy and cardiovascular disease: Lessons from a monkey model of postmenopausal women. ILAR J 2004;2:139-146.